News - Tysabri

Filter

Current filters:

Tysabri

Popular Filters

New analysis of risk stratification for Biogen and Elan's Tysabri

20-05-2012

US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

Elan back in the black, boosted by Tysabri

09-02-2012

Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…

BiotechnologyElanFinancialTysabri

FDA updates Tysabri label relating to anti-JCV

23-01-2012

The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates

19-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

EU clears anti-JC virus risk labeling for Biogen and Elan’s Tysabri

23-06-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan (NYSE: ELN) said yesterday that the…

Biogen IdecBiotechnologyElanEuropeNeurologicalRegulationTysabri

Biogen Idec shares leap, as 1st-qtr 2011 earnings rocket, boosted by Tysabri; and by MS drug results

26-04-2011

Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) soared 20% to $104.11 in pre-market trading last…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTysabri

Company Spotlight

Fibrotech

Fibrotech

Back to top